Oyster Point Pharma

Commercial-stage biopharmaceutical company focused on pharmaceutical therapies to treat ophthalmic diseases.

Add To Watchlist
General Information
Company Name
Oyster Point Pharma
Founded Year
2015
Location (Offices)
Princeton, United States +2
Founders / Decision Makers
Donald J. Santel - Non-executive Chairperson, Director Michael Ackermann - Chairman Loni da Silva - Senior Vice President, Regulatory Affairs Mark Murray - CFO Jeffrey Nau - CEO Patricia Johnson - Executive Director, Regulatory CMC JOHN SNISARENKO - Chief Commercial Officer
Number of Employees
88
Industries
Biopharma, Health Care, Pharmaceutical
Funding Stage
Post Ipo Equity
Social Media

Oyster Point Pharma - Company Profile

Oyster Point Pharma is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases. Founded in 2015 and headquartered in the United States, the company has garnered notable attention with its recent $120.80M Post-IPO Equity investment on 12 May 2020. Oyster Point Pharma's commitment to addressing unmet medical needs in the field of ophthalmology aligns with the significant demand for innovative treatments in the Biopharma, Health Care, and Pharmaceutical industries. With its clear focus and promising developments, Oyster Point Pharma demonstrates potential for growth and impact in the biopharmaceutical market.

Taxonomy: biopharmaceutical company, ophthalmic diseases, clinical-stage, pharmaceutical therapies, ocular surface diseases, OC-01, nicotinic acetylcholine receptor, dry eye disease, tear film homeostasis, Lacrimal Functional Unit, pharmaceutical development, innovative treatments, nasal spray, medical research, healthcare industry

Funding Rounds & Investors of Oyster Point Pharma (3)

View All
Funding Stage Amount No. Investors Investors Date
Post-IPO Equity $120.80M - 12 May 2020
Series B $93.00M 5
New Enterprise Associates, investor in Oyster Point Pharma's Series B round Versant Ventures, investor in Oyster Point Pharma's Series B round Invus, investor in Oyster Point Pharma's Series B round Flying L Partners, investor in Oyster Point Pharma's Series B round Vida Ventures, investor in Oyster Point Pharma's Series B round
26 Feb 2019
Series A $22.00M 2
New Enterprise Associates, investor in Oyster Point Pharma's Series A round Versant Ventures, investor in Oyster Point Pharma's Series A round
07 Nov 2017

Latest News of Oyster Point Pharma

View All

No recent news or press coverage available for Oyster Point Pharma.

Similar Companies to Oyster Point Pharma

View All
Ingenium Pharmaceuticals GmbH - Similar company to Oyster Point Pharma
Ingenium Pharmaceuticals GmbH
TrippBio - Similar company to Oyster Point Pharma
TrippBio Redefining Treatment for Respiratory Viruses
Danking Pharmaceuticals - Similar company to Oyster Point Pharma
Danking Pharmaceuticals Pioneering advancements in oncology and therapeutic research for cancer, inflammation, blood, and metabolic diseases.
Eisai US - Similar company to Oyster Point Pharma
Eisai US Breaking through in the therapeutic areas of oncology and neurology. View our community guidelines: https://bit.ly/3dkY
Corvidane - Similar company to Oyster Point Pharma
Corvidane A novel approach to treating cardiovascular and liver diseases
Circle Decoration Circle Decoration

Want to dive deeper into Oyster Point Pharma? Join now to access exclusive insights and find similar companies like this — powered by AI analytics.

Register Now